En la esclerosis sistémica, el esófago se afecta en un 90%, seguido de los tramos anorrectal (%), gástrico ( 70%), colon (%) e intestino delgado. La esclerodermia es un relativamente infrecuente enfermedad reumática autoinmunitaria que afecta la piel y otros órganos del cuerpo. La esclerosis sistémica es una enfermedad autoinmune del tejido conectivo, que se caracteriza por un depósito excesivo de tejido colágeno y otros.

Author: Tubei Meztinos
Country: Equatorial Guinea
Language: English (Spanish)
Genre: Career
Published (Last): 17 November 2014
Pages: 54
PDF File Size: 15.13 Mb
ePub File Size: 4.91 Mb
ISBN: 429-9-15671-549-4
Downloads: 24690
Price: Free* [*Free Regsitration Required]
Uploader: Mer

Important complications of fibrosis include left ventricular hypertrophy, as well as systolic and diastolic dysfunction of both ventricles. The knowledge of the aistemica of systemic sclerosis to molecular level will lead to new treatment strategies.

Nailfold capillaroscopy in the screening and diagnosis of Raynaud’s phenomenon. Cyclosporine in systemic sclerosis. Si continua navegando, consideramos que acepta su uso.

Nat Clin Pract Rheumatol, 2pp. J Rheumatol, 6pp. Long-term low molecular weight heparin therapy for severe Raynaud’s phenomenon: B thromboglobulin and platelet factor 4 in bronchoalveolar lavage fluid of patients with systemic sclerosis. Pathogenesis of systemic sclerosis scleroderma. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: Autoimmun Rev, 4pp.


Br J Rheumatol, 35pp. Z Rheumatol, 63pp. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Prevalence of Raynaud’s phenomenon in a healthy Spanish population. Association of skeletal myositis with myocardial disease has been described.

There was a problem providing the content you requested

Evolution of primary Raynaud’s phenomenon to connective tissue disease. Long-term outcome in mixed connective tissue disease: Ann Rheum Dis, 56pp.

Medicine Baltimore81pp. Am Heart J, 95pp. J Nucl Med, 42pp.

Bosentan therapy for patients with severe Raynaud’s phenomenon in systemic sclerosis. Anti-endothelial cell antibodies in systemic sclerosis: Ann Intern Med,pp.

Effect of ketanserin on Raynaud’s phenomenon in progressive systemic sclerosis: Contraction band necrosis is the typical pathological finding. Rheumatology, 10pp. D-Penillamine therapy in progressive systemic sclerosis scleroderma. Pericardial tamponade in systemic sclerosis scleroderma. Detection of early impairment of coronary flow reserve in patients with systemic esc,erosis.

To improve our services and esclerosjs, we use “cookies” own or third parties authorized to show advertising related to client preferences through the analyses of navigation customer behavior. Scand J Rheumatol, 33pp. Disturbed right ventricular diastolic function in patients with systemic sclerosis: Clin Rheumatol, 14pp.


Br J Rheumatol, 35pp. Curr Rheumatol Rep, 7pp.

Tratamiento de la esclerosis sistémica | Reumatología Clínica

Vascular involvement in systemic sclerosis [review]. Arthritis Rheum, 34pp.

Am J Med, 80pp. Treatment of systemic sclerosis by potentially disease-modifying distemica. Electroanatomic mapping and ablation of ventricular tachycardia associated with systemic sclerosis.

J Reumatol, 20pp. Minerva Cardioangiol, 47pp. A randomized, controlled trial.